Likewise, the LocoMMotion study demonstrated poor clinical outcomes in triple-class–exposed patients (who received at least a PI, IMiD, and anti-CD38 mAb) with R/R MM in a real-world setting, reinforcing the need for therapies with novel mechanisms of action [36]. This evidence concerns the gene CD38 and Miyoshi myopathy.